Second malignancies after allogeneic hematopoietic stem cell transplantation: new insight and current problems

Blood Reviews - Tập 16 - Trang 135-146 - 2002
L. Adès1, P. Guardiola1, G. Sociè1
1Service d'Hématologie-Greffe de Moelle, Hôpital Saint Louis, Paris, France

Tài liệu tham khảo

Deeg, 1998, Malignancies after hematopoietic stem cell transplantation: many questions, some answers, Blood, 91, 1833, 10.1182/blood.V91.6.1833

Pedersenbjergaard, 2000, Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation, Blood, 95, 3273, 10.1182/blood.V95.11.3273

Socie, 1995, Malignant diseases after bone marrow transplantation: the case for tumor banking and continued reporting to registries, Bone Marrow Transplant., 16, 493

Cohen, 1991, Epstein–Barr virus lymphoprolifeartive disease associated with acquired immunodeficiency, Medicine, 70, 137, 10.1097/00005792-199103000-00005

Socie, 1992, Malignant disease after allogeneic bone marrow transplantation: the case for assessment of risk factors, Br J Haematol, 80, 427, 10.1111/j.1365-2141.1992.tb04553.x

Socie, 1994, Malignant Diseases After Allogeneic Bone Marrow Transplantation – an Updated Overview, Nouv Rev Fr Hematol, 36, S75

O'Reilly, 1996, 149

Witherspoon, 1994, Secondary malignancies after marrow transplantation for leukemia or aplastic anemia, Transplantation, 57, 1413, 10.1097/00007890-199405000-00001

Curtis, 1999, Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study, Blood, 94, 2208

Simon, 1991, Fatal B-cell lymphoproliferative syndrome in allogeneic marrow graft recipients, Virchows Arch.[B[., 60, 307, 10.1007/BF02899562

Shapiro, 1988, Epstein–Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation, Blood, 71, 1234, 10.1182/blood.V71.5.1234.1234

Zutter, 1988, Epstein–Barr virus lymphoproliferation after marrow transplantation, Blood, 72, 520, 10.1182/blood.V72.2.520.520

Davey, 1989, Epstein–Barr virus-related lymphoproliferative disorders following bone marrow transplantation; an immunologic and genotypic analysis, Modern Pathol, 2, 27

Orazi, 1997, Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features, Am J Clin Pathol, 07, 419, 10.1093/ajcp/107.4.419

Seiden, 1993, Molecular genetic analysis of post-transplant lymphoproliferative disorders, Hematol Oncol Clin N Amer, 7, 447, 10.1016/S0889-8588(18)30251-X

Cleary, 1988, Clonal analysis of transplant-associated lymphoproliferation base on the structure of the genomic termini of Epstein–Barr virus, Blood, 349, 10.1182/blood.V72.1.349.bloodjournal721349

Knowles, 1997, Correlative morphologic and molecular geneitc analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders, Blood, 85, 552, 10.1182/blood.V85.2.552.552

Chadburn, 1995, Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin, Am J Pathol, 47, 1862

Papadopoulos, 1994, Infusions of donor leukocytes to treat Epstein–Barr virus – associated lymphoproliferative disorders after allogeneic bone marrow transplantation, N Engl J Med, 30, 1185, 10.1056/NEJM199404283301703

Young, 1989, Expression of Epstein–Barr virus transformation-associated genes in tissue of patients with EBV lymphoproliferative disease, N Engl J Med, 21, 1080, 10.1056/NEJM198910193211604

Suhrbier, 1993, Peptide epitope Induced apoptosis of human cytotoxic T-lymphocytes – implications for peripheral T-cell deletion and peptide vaccination, J Immunol, 50, 2169, 10.4049/jimmunol.150.6.2169

Cen, 1993, Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders, Blood, 81, 1393, 10.1182/blood.V81.5.1393.1393

Mcknight, 1994, EBV gene expression, EBNA antibody responses and EBV+ peripheral blood lymphocytes in post-transplant lymphoproliferative disease, Leuk Lymphoma, 15, 9, 10.3109/10428199409051672

Randhawa, 1992, Expression of Epstien–Barr virus encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease, N Engl J Med, 27, 1710, 10.1056/NEJM199212103272403

Delecluse, 1995, Post-transplant lymphoproliferative disorders with genetic abnormalities commonly found in malignant tumours, Br J Haematol, 89, 90, 10.1111/j.1365-2141.1995.tb08905.x

Witherspoon, 1989, Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia, N Engl J Med, 21, 784, 10.1056/NEJM198909213211203

Bhatia, 1996, Malignant neoplasms following bone marrow transplantation, Blood, 87, 3633, 10.1182/blood.V87.9.3633.bloodjournal8793633

Kernan, 1993, Analysis of 462 Transplantations from Unrelated Donors Facilitated by the National Marrow Donor Program, N Engl J Med, 28, 593, 10.1056/NEJM199303043280901

Hale, 1998, Risks of developing Epstein–Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants, Blood, 91, 3079, 10.1182/blood.V91.8.3079.3079_3079_3083

Milpied, 1999, Epstein-Barr virus-associated B cell lymphoproliferative disease after non-myeloablative allogeneic stem cell transplantation, Bone Marrow Transplant., 23, 629, 10.1038/sj.bmt.1701628

Klein, 1997, Epstein–Barr virus strategy in normal and neoplastic B cells, Cell, 77, 791, 10.1016/0092-8674(94)90125-2

Frank, 1995, Posttransplantation lymphoproliferative disorders frequently contain type A and not type B Epstein–Barr virus, Blood, 85, 1396, 10.1182/blood.V85.5.1396.bloodjournal8551396

Kingma, 1996, Epstein-barr virus latent membrane protein-1 oncogene deletions: correlation with malignancy in Epstein–Barr virus-associated lymphoproliferative disorders and malignant lymphomas, Blood, 88, 242, 10.1182/blood.V88.1.242.242

Klein, 1995, EBV-associated lymphoproliferative syndrome with a distinct 69 base-pair deletion in the LMP-1 oncogene, Br J Haematol, 91, 938, 10.1111/j.1365-2141.1995.tb05416.x

Gottschalk, 2001, An Epstein–Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs, Blood, 97, 835, 10.1182/blood.V97.4.835

Crawford, 1986, Epstein–Barr virus infection and immunity in bone marrow transplant recipients, Transplantation, 42, 50, 10.1097/00007890-198607000-00010

Lucas, 1996, The development of cellular immunity to Epstein–Barr virus after allogeneic bone marrow transplantation, Blood, 87, 2594, 10.1182/blood.V87.6.2594.bloodjournal8762594

Lacerda, 1996, Human Epstein–Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice, J Exp Med, 83, 1215, 10.1084/jem.183.3.1215

Heslop, 1996, Long-term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes, Nature Med, 2, 551, 10.1038/nm0596-551

Rooney, 1995, Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr virus-related lymphoproliferation, Lancet, 45, 9, 10.1016/S0140-6736(95)91150-2

Baiocchi, 2001, GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein–Barr virus lymphoproliferative disorder, J Clin Invest, 08, 887, 10.1172/JCI12932

Gustafsson, 2000, Epstein–Barr virus (EBV) load in bone marrow transplant recipients at risk to develop post-transplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells, Blood, 95, 807, 10.1182/blood.V95.3.807.003k24_807_814

Stevens, 2001, Frequent monitoring of Epstein–Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients, Blood, 97, 1165, 10.1182/blood.V97.5.1165

van Esser, 2001, Epstein–Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell – depleted SCT, Blood, 98, 972, 10.1182/blood.V98.4.972

van Esser, 2001, Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein–Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation, Br J Haematol, 13, 814, 10.1046/j.1365-2141.2001.02789.x

Marshall, 2000, Rapid reconstitution of Epstein–Barr virus-specific T lymphocytes following allogeneic stem cell transplantation, Blood, 96, 2814, 10.1182/blood.V96.8.2814

Rooney, 1995, Early identification of Epstein–Barr virus-associated post-transplantation lymphoproliferative disease, Br J Haematol, 89, 98, 10.1111/j.1365-2141.1995.tb08904.x

Kenacy, 1995, Epstein–Barr virus DNA in peripheral blood leukocytes of patients with post-transplant lymphoproliferative disease, Transplantation, 60, 547, 10.1097/00007890-199509270-00005

Riddler, 1994, Increased levels of circulating Epstein–barr virus-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttranslant lymphoproliferative disease in solid-organ transplant recipients, Blood, 84, 972, 10.1182/blood.V84.3.972.972

Savoie, 1994, Direct Correlation Between the Load of Epstein–Barr Virus-Infected Lymphocytes in the Peripheral Blood of Pediatric Transplant Patients and Risk of Lymphoproliferative Disease, Blood, 83, 2715, 10.1182/blood.V83.9.2715.2715

Benkerrou, 1993, Therapy for transplant-related lymphoproliferative diseases, Hematol Oncol Clin N Amer, 7, 467, 10.1016/S0889-8588(18)30252-1

Sullivan, 1984, Epstein–Barr virus induced lymphoproliferation: implications for antiviral chemotherapy, N Engl J Med, 11, 1163, 10.1056/NEJM198411013111806

Swinnen, 1995, Aggressive treatment for postcardiac transplant lymphoproliferation, Blood, 86, 3333, 10.1182/blood.V86.9.3333.bloodjournal8693333

Shapiro, 1988, Treatment of B-cell lymphoprolifertive disorders with interferon alpha and intravenous gamma globulin, N Engl J Med, 18, 1334

Fischer, 1991, Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferativesyndrome following marrow and organ transplantation, N Engl J Med, 24, 1451, 10.1056/NEJM199105233242102

Blanche, 1997, Treatment of Epstein–Barr virus-induced polyclonal B-lymphocyte proliferation by anti-B-cell monoclonal antibodies, Ann Int Med, 08, 199

Benkerrou, 1998, Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome, Blood, 92, 3137, 10.1182/blood.V92.9.3137

Durandy, 1992, Control of human B cell tumor growth in severe combined immunodeficiency mice by monoclonal anti-B cell antibodies, J Clin Invest, 90, 945, 10.1172/JCI115971

Tanner, 1994, Interleukin-6 and Epstein–Barr virus induction by cyclosporin A: potential role in lymhoproliferative disease, Blood, 84, 3956, 10.1182/blood.V84.11.3956.bloodjournal84113956

Haddad, 2001, Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1–2 clinical trial, Blood, 97, 1590, 10.1182/blood.V97.6.1590

Kuehnle, 2000, CD20 monoclonal antibody (rituximab) for therapy of Epstein–Barr virus lymphoma after hemopoietic stem-cell transplantation, Blood, 95, 1502, 10.1182/blood.V95.4.1502.004k40_1502_1505

Milpied, 2000, Humanized anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients, Ann Oncol, 11, S113, 10.1093/annonc/11.suppl_1.S113

Faye, 2001, Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children, Br J Haematol, 15, 112, 10.1046/j.1365-2141.2001.03041.x

Papadopoulos, 1996, Current results of donor leukocyte infusions for treatment of Epstien–Barr virus associated lymphoproloiferative disorders following related and unrelated T cell depleted bone marrow transplant, Blood, 88, 681a

Heslop, 1996, Efficacy of adoptively transferred virus specific cytotoxic lymphocytes for prophylaxis and treatment of EBV lymphoma, Blood, 88, 681a

Bonini, 1997, HSV-TK gene transfer into donor-lymphocytes for control of allogeneic graft-versus leukemia, Science, 76, 1719, 10.1126/science.276.5319.1719

Lieberman, 1994, Using T cells to treat B-cell cancers, N Engl J Med, 30, 1231, 10.1056/NEJM199404283301711

Emanuel, 1997, Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes, Transplantation, 63, 1691, 10.1097/00007890-199706150-00027

Hanson, 1996, Posttransplant T-cell lymphoproliferative disorders: an aggressive, late compication of solid-organ transplantation, Blood, 88, 3626, 10.1182/blood.V88.9.3626.bloodjournal8893626

Vangorp, 1994, Post-transplant T-cell lymphoma – Report of three cases and a review of the literature, Cancer, 73, 3064, 10.1002/1097-0142(19940615)73:12<3064::AID-CNCR2820731227>3.0.CO;2-0

Zutter, 1990, Secondary T-cell lymphoproliferation after marrow transplantation, Am J Clin Pathol, 94, 714, 10.1093/ajcp/94.6.714

Socie, 1996, Secondary malignancies, Curr Opin Hematol, 3, 466, 10.1097/00062752-199603060-00011

Meignin, 1998, Hodgkin's disease of donor origin after allogeneic bone marrow transplantation for myelogeneous chronic leukemia, Transplantation, 65, 595, 10.1097/00007890-199802270-00028

Verschuur, 1994, Donor B cell lymphoma of the brain after allogeneic bone marrow transplantation for acute myeloid leukemia, Bone Marrow Transplant, 14, 467

Shustik, 1995, A solitary plasmocytoma of donor origin arising 14 years after kidney allotransplantation, Br J Haematol, 91, 167, 10.1111/j.1365-2141.1995.tb05263.x

O'Riordan, 1994, Localized, late-onset, high-grade lymphoma following bone marrow transplantation: response to combination chemotherapy, Br J Haematol, 86, 183, 10.1111/j.1365-2141.1994.tb03272.x

Trimble, 1993, B-Cell Lymphoma of Recipient Origin 9 Years After Allogeneic Bone Marrow Transplantation for T-Cell Acute Lymphoblastic Leukaemia, Br J Haematol, 85, 99, 10.1111/j.1365-2141.1993.tb08651.x

Schouten, 1995, Large-cell anaplastic non-Hodgkin's lymphoma originating in donor cells after allogeneic bone marrow transplantation, Br J Haematol, 91, 162, 10.1111/j.1365-2141.1995.tb05262.x

Rowlings, 1999, Increased incidence of Hodgkin's disease after allogeneic bone marrow transplantation, J Clin Oncol, 17, 3122, 10.1200/JCO.1999.17.10.3122

Broerse, 1981, Tumour induction in Rhesus monkeys after total body irradiation with X-rays and fission neutrons, Int J Radiat Biol Relat Stud Phys Chem Med, 40, 671, 10.1080/09553008114551661

Deeg, 1983, Increased incidence of malignant tumors in dogs after total body irradiation and marrow transplantation, Int J Radiat Oncol Biol Phys, 9, 1505, 10.1016/0360-3016(83)90325-5

Deeg, 1993, Risk Factors for the Development of Secondary Malignancies After Marrow Transplantation, Hematol Oncol Clin N Amer, 7, 417, 10.1016/S0889-8588(18)30249-1

Deeg, 1984, Secondary malignancies after marrow transplantation, Exp Hematol, 12, 660

Lowsky, 1994, Secondary malignancies after bone marrow transplantation in adults, J Clin Oncol, 12, 2187, 10.1200/JCO.1994.12.10.2187

Socie, 1991, Increased incidence of solid malignant tumors after bone marrow transplantation for severe aplastic anemia, Blood, 78, 277, 10.1182/blood.V78.2.277.277

Deeg, 1996, Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: A joint Seattle and Paris analysis of results in 700 patients, Blood, 87, 386, 10.1182/blood.V87.1.386.386

Curtis, 1997, Solid cancers after bone marrow transplantation, N Engl J Med, 36, 897, 10.1056/NEJM199703273361301

Socie, 2000, New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia, J Clin Oncol, 18, 348, 10.1200/JCO.2000.18.2.348

Rizzo, 2000, Solid cancers in survivors of allogeneic bone marrow transplantation, Blood, 96, 557a

Socie, 1998, Squamous cell carcinomas after allogeneic bone marrow transplantation for aplastic anemia – Further evidence of a multistep process, Transplantation, 66, 667, 10.1097/00007890-199809150-00023

Daneshpouy, 2001, Human papillomavirus infection and anogenital condyloma in bone marrow transplant recipients, Transplantation, 71, 167, 10.1097/00007890-200101150-00030

Bhatia, 2001, Solid cancers after bone marrow transplantation, J Clin Oncol, 19, 464, 10.1200/JCO.2001.19.2.464

Favre-Schmuziger, 2000, Treatment of solid tumors following allogeneic bone marrow transplantation, Bone Marrow Transplant, 25, 895, 10.1038/sj.bmt.1702339

Fialkow, 1971, Leukaemic transformation of engrafted human marrow cells in vivo, Lancet, 1, 251, 10.1016/S0140-6736(71)90998-6

Thomas, 1972, Leukaemic transformation of engrafted human marrow cells in vivo, Lancet, 1, 1310, 10.1016/S0140-6736(72)91037-9

Browne, 1991, Donor-cell leukemia after bone marrow transplantation for severe aplastic anemia, N Engl J Med, 25, 710, 10.1056/NEJM199109053251007

Thông tin
Thông tin xuất bản

Blood Reviews

Tập 16

135-146

Thông tin tác giả